Tg32 mice (also called hFcRn Tg32 or FcRn-/- hFcRn line 32 Tg) carry a knock-out mutation for the mouse Fcgrt (Fc receptor, IgG, alpha chain transporter) gene and a transgene expressing the human FCGRT gene under the control of its own native promoter (hTg32). Useful in evaluating the pharmacokinetics and pharmacodynamics of human immunoglobulin G (IgG) and Fc-domain based therapeutics, homozygous Tg32 mice have the highest, most human-like protection of humanized IgG and are the best model for use when maximum half-life data is required.
Need assistance evaluating antibodies in FcRn mice? Human preclinical pharmacokinetic (PK) analysis is available. See our FcRn full service platform.
Dr. Derry Roopenian, The Jackson Laboratory
|Allele Type||Gene Symbol||Gene Name|
|Targeted (Null/Knockout)||Fcgrt||Fc receptor, IgG, alpha chain transporter|
|Transgenic (Inserted expressed sequence, Humanized sequence)|
There are several challenges facing researchers who are developing antibody-based therapeutics, including assessing half-life, selecting efficacious variants, and determining dosage for clinical trials. The mechanism behind IgG's extended half-life lies in the interaction between IgG and the neonatal Fc receptor (FcRn), encoded by Fcgrt, Fc receptor, IgG, alpha chain transporter (Roopenian et al., 2003; Challa et al., 2014). Standard rodent models are problematic in that mouse and rat FcRn do not bind human IgG with the same affinity as human FcRn, leading to inaccurate half-life data (Ober et al., 2001).
Tg32 (Stock No. 014565) and Tg276 (Stock No. 004919) are humanized mouse models that can be used to predict the pharmacokinetics (PK) of IgG antibodies in humans with an accuracy comparable to non-human primates (NHPs). Both carry a knock-out mutation for the mouse Fcgrt gene (Stock No. 003982) in addition to a transgene expressing the human FCGRT gene either under the control of its own native promoter (Stock No. 014565) or under the control of the more broadly-expressed CAG promoter (human cytomegalovirus (CMV) enhancer fused to the chicken beta-actin; Stock No. 004919). Each line has its unique attributes and optimal applications.
Tg32 mice (also called hFcRn Tg32 or FcRn-/- hFcRn line 32 Tg; Stock No. 014565) express the human FCGRT transgene from the native human promoter, and have the highest, most human-like protection of humanized IgG and are the best model for use when maximum half-life data is required. The transgene, integrated on mouse Chromosome 2, displays a physiological human FCGRT expression pattern (Latvala et al., 2017). Experimental variability between the mice is minimal, enabling a small number of animals per study. Using this model and human PK-predictive allometric scaling (Betts et al., 2018), clinicians can estimate the minimum dose to achieve therapeutic serum concentrations, reducing the need for potentially risky dose-escalation treatments during clinical trials. Avery et al., 2016 show that monoclonal antibody clearance in homozygous mice correlates with human pharmacokinetics better than non-human primates. In this line, serum albumin levels are slightly above those seen in C57BL/6J mice, while mouse IgG levels are low due to the species-specific activity of human FCGRT.
Immunodeficient FCGRT-humanized models carrying the Tg32 transgene are also available to evaluate Fc-domain based therapeutics that are potentially immunogenic or involve xenografts - see B6.Cg-Fcgrttm1Dcr Prkdcscid Tg(FCGRT)32Dcr/DcrJ (Stock No. 018441), and NOD.Cg-Fcgrttm1Dcr Prkdcscid Il2rgtm1Wjl Tg(FCGRT)32Dcr/J (Stock No. 028615).
Tg276 mice (Stock No. 004919) express the human FCGRT transgene from the broadly-expressed CAG promoter (human cytomegalovirus (CMV) enhancer fused to the chicken beta-actin). Plasma albumin levels are similar to wild-type mice, however the serum IgG levels remain low due to the species-specific behavior of human FCGRT. These mice are best suited to detect subtle differences in antibody persistence in vivoTg276 model lies in its ability to allow fine distinctions in half-life between several candidate molecules. Longer IgG half-lives are observed in homozygotes, as compared to hemizygotes. Petkova et al., 2006 demonstrate that antibody half-life in Tg32 hemizygotes (Stock No. 014565) is comparable to that of Tg276 (Stock No. 004919) homozygotes.
These knock-out/transgenic mice were generated in the laboratory of Dr. Derry Roopenian (The Jackson Laboratory) by crossing Fcgrttm1Dcr mutant mice with Tg(FCGRT)32Dcr transgenic mice (coisogenic on a C57BL/6J genetic background). These double mutant mice were backcrossed for 11 generations to C57BL/6J prior to transfer to The Jackson Laboratory Repository.
To generate the FcRn α-chain knock-out mice (Fcgrttm1Dcr; see also Stock No. 003982), a targeting vector was designed to replace 1588 nucleotide fragments (encoding promoter sequence 5' of the transcriptional start site, exon1, intron 2, and most of exon2) of the Fc receptor, IgG, alpha chain transporter gene (Fcgrt) on chromosome 7 with a PGK-Neor cassette. The vector was electroporated into 129/SvJ-derived ESV/J-1182 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts. The resulting chimeric animals were crossed to C57BL/6J mice.
To generate the hFcRn line 32 transgenic mice, a 33-Kb cosmid clone including the complete human FCGRT gene (approximately 11kb as well as 10kb of 5' and 3' flanking sequences) was microinjected into fertilized C57BL/6J mouse eggs. Founder line 32 was established. Transgene insertion occurred on mouse Chromosome 2.
|Expressed Gene||FCGRT, Fc fragment of IgG receptor and transporter, human|
|Site of Expression|
|Allele Name||targeted mutation 1, Derry C Roopenian|
|Allele Type||Targeted (Null/Knockout)|
|Gene Symbol and Name||Fcgrt, Fc receptor, IgG, alpha chain transporter|
|Strain of Origin||129X1/SvJ|
|Molecular Note||Sequence from exon 1 and part of exon2 was replaced with a PGK-neo cassette. Quantitative PCR of liver cDNA indicated the absence of mRNA. Western blot analysis of neonatal intestinal extracts failed to reveal protein product.|
|Allele Name||transgene insertion 32, Derry C Roopenian|
|Allele Type||Transgenic (Inserted expressed sequence, Humanized sequence)|
|Allele Synonym(s)||hFcRn(32) vhFcRn (32) Tg hFcRn (32) Tg; Tg32|
|Gene Symbol and Name||Tg(FCGRT)32Dcr, transgene insertion 32, Derry C Roopenian|
|Promoter||FCGRT, Fc fragment of IgG receptor and transporter, human|
|Expressed Gene||FCGRT, Fc fragment of IgG receptor and transporter, human|
|Strain of Origin||C57BL/6J|
|Molecular Note||A 34Kb fragment of a BAC containing the entire human FCGRT , Fc fragment of IgG, receptor, transporter, alpha, gene (approximately 11kb) and approximately 10kb of flanking sequence was sublconed into a SuperCos vector. The resulting cosmid was microinjected into fertilized C57BL/6J mouse eggs. Founder line 32 was established. Transgene insertion occurred on Chr 2.|
When maintaining a live colony, mice homozygous for the Fcgrttm1Dcr allele and homozygous for the Tg(FCGRT)32Dcr transgene can be bred together.
When using the FcRn-/- hFcRn (32) Tg, hFcRn Tg32, Tg32
mouse strain in a publication, please cite the originating article(s) and include JAX stock #014565 in your Materials and Methods section.
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.
MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.
Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.